title: Tailoring mTOR-based therapy: molecular evidence and clinical challenges.
abstract: The mTOR signaling pathway integrates inputs from a variety of upstream stimuli to regulate diverse cellular processes including proliferation, growth, survival, motility, autophagy, protein synthesis and metabolism. The mTOR pathway is dysregulated in a number of human pathologies including cancer, diabetes, obesity, autoimmune disorders, neurological disease and aging. Ongoing clinical trials testing mTOR-targeted treatments number in the hundreds and underscore its therapeutic potential. To date mTOR inhibitors are clinically approved to prevent organ rejection, to inhibit restenosis after angioplasty, and to treat several advanced cancers. In this review we discuss the continuously evolving field of mTOR pharmacogenomics, as well as highlight the emerging efforts in identifying diagnostic and prognostic markers, including miRNAs, in order to assess successful therapeutic responses.
authors.affiliation: Department of Physiology & Cellular Biophysics, The Clyde & Helen Wu Center for Molecular Cardiology, Columbia University Medical Center, New York, NY 10032, USA.
authors.forename: Gaetano
authors.initials: G
authors.lastname: Santulli
authors.forename: Hana
authors.initials: H
authors.lastname: Totary-Jain
mesh_terms: D000375:Aging; D006801:Humans; D035683:MicroRNAs / Q000037:antagonists & inhibitors / Q000235:genetics*; D058990:Molecular Targeted Therapy; D009369:Neoplasms / Q000235:genetics* / Q000473:pathology; D010597:Pharmacogenetics; D015398:Signal Transduction / Q000235:genetics; D058570:TOR Serine-Threonine Kinases / Q000037:antagonists & inhibitors / Q000235:genetics*
chemical_list: D035683:MicroRNAs; C546842:MTOR protein, human; D058570:TOR Serine-Threonine Kinases
references.citation: J Clin Invest. 2010 Aug;120(8):2858-66
references.pmid: 20664172
references.citation: Cell. 2012 Mar 16;148(6):1172-87
references.pmid: 22424228
references.citation: J Virol. 2008 Sep;82(18):9065-74
references.pmid: 18596100
references.citation: Mol Cancer Ther. 2008 Jul;7(7):1851-63
references.pmid: 18606717
references.citation: Breast Cancer Res Treat. 2012 Jan;131(2):425-36
references.pmid: 21394501
references.citation: Mol Cancer Ther. 2011 Nov;10(11):2189-99
references.pmid: 21750219
references.citation: Br J Haematol. 2009 Apr;145(1):101-6
references.pmid: 19208097
references.citation: Biochem Soc Trans. 2009 Feb;37(Pt 1):217-22
references.pmid: 19143635
references.citation: J Clin Invest. 1996 Nov 15;98(10):2277-83
references.pmid: 8941644
references.citation: Cancer Res. 2010 Jun 1;70(11):4666-75
references.pmid: 20484036
references.citation: Mol Endocrinol. 2010 Feb;24(2):447-63
references.pmid: 20081105
references.citation: Biochemistry. 1992 Mar 3;31(8):2427-34
references.pmid: 1371698
references.citation: Cell. 2012 Apr 13;149(2):274-93
references.pmid: 22500797
references.citation: Mol Endocrinol. 2000 Jun;14(6):783-94
references.pmid: 10847581
references.citation: Nat Rev Drug Discov. 2009 Jul;8(7):535-6
references.pmid: 19568281
references.citation: Cell. 1993 May 7;73(3):585-96
references.pmid: 8387896
references.citation: Mol Pharmacol. 2012 Dec;82(6):1230-40
references.pmid: 22989521
references.citation: Science. 1996 Jul 12;273(5272):239-42
references.pmid: 8662507
references.citation: J Antibiot (Tokyo). 1975 Oct;28(10):727-32
references.pmid: 1102509
references.citation: Transplant Proc. 1995 Feb;27(1):430-1
references.pmid: 7879049
references.citation: Target Oncol. 2011 Jun;6(2):119-24
references.pmid: 21533544
references.citation: Mol Cancer Ther. 2012 Aug;11(8):1758-69
references.pmid: 22848094
references.citation: J Clin Oncol. 2005 Aug 10;23(23):5347-56
references.pmid: 15983389
references.citation: Sci Transl Med. 2012 Jun 20;4(139):139ra84
references.pmid: 22539746
references.citation: J Clin Oncol. 2009 Aug 10;27(23):3822-9
references.pmid: 19581539
references.citation: J Clin Invest. 2008 Sep;118(9):3065-74
references.pmid: 18725988
references.citation: CA Cancer J Clin. 2009 Mar-Apr;59(2):111-37
references.pmid: 19278961
references.citation: Pharmacogenomics. 2010 May;11(5):629-32
references.pmid: 20415550
references.citation: Future Oncol. 2012 Dec;8(12):1515-23
references.pmid: 23231513
references.citation: Pediatr Blood Cancer. 2012 Feb;58(2):191-9
references.pmid: 21337679
references.citation: Leukemia. 2012 Jun;26(6):1195-202
references.pmid: 22143671
references.citation: Proc Natl Acad Sci U S A. 2001 Aug 28;98(18):10314-9
references.pmid: 11504908
references.citation: Circulation. 1999 Apr 27;99(16):2164-70
references.pmid: 10217658
references.citation: Oncogene. 2011 Aug 11;30(32):3489-501
references.pmid: 21383697
references.citation: Cell Cycle. 2013 Mar 15;12(6):861-2
references.pmid: 23442794
references.citation: Clin Cancer Res. 2012 May 1;18(9):2603-12
references.pmid: 22407832
references.citation: Mol Cell Biol. 1993 Oct;13(10):6012-23
references.pmid: 8413204
references.citation: Nat Med. 2002 Feb;8(2):128-35
references.pmid: 11821896
references.citation: Cancer Res. 2010 Jan 1;70(1):288-98
references.pmid: 20028854
references.citation: Bioorg Med Chem Lett. 2013 Mar 1;23(5):1212-6
references.pmid: 23375793
references.citation: Circulation. 2011 Mar 8;123(9):999-1009
references.pmid: 21339483
references.citation: J Med Chem. 2010 Mar 25;53(6):2636-45
references.pmid: 20166697
references.citation: Curr Top Microbiol Immunol. 2010;347:209-39
references.pmid: 20582534
references.citation: Mol Cell Biol. 1991 Mar;11(3):1718-23
references.pmid: 1996117
references.citation: Med Oncol. 2013 Mar;30(1):411
references.pmid: 23292834
references.citation: Apoptosis. 2004 Nov;9(6):797-805
references.pmid: 15505422
references.citation: Cancer Res. 2011 Sep 1;71(17):5765-78
references.pmid: 21795477
references.citation: J Antibiot (Tokyo). 1975 Oct;28(10):721-6
references.pmid: 1102508
references.citation: Proc Natl Acad Sci U S A. 1995 May 23;92(11):4947-51
references.pmid: 7539137
references.citation: Mol Cell. 2011 Apr 8;42(1):84-95
references.pmid: 21474070
references.citation: Circ Res. 1995 Mar;76(3):412-7
references.pmid: 7532117
references.citation: Mol Cell Biol. 2001 Aug;21(15):5050-62
references.pmid: 11438661
references.citation: Int J Cancer. 2013 Aug 15;133(4):788-96
references.pmid: 23319457
references.citation: Proc Natl Acad Sci U S A. 2010 Sep 14;107(37):16228-33
references.pmid: 20805506
references.citation: Proc Natl Acad Sci U S A. 2008 Nov 11;105(45):17414-9
references.pmid: 18955708
references.citation: J Cell Biochem. 2013 Jul;114(7):1625-33
references.pmid: 23355454
references.citation: Br J Cancer. 2012 Sep 25;107(7):1093-9
references.pmid: 22935583
references.citation: Mol Med Rep. 2012 Sep;6(3):675-81
references.pmid: 22751686
references.citation: Cancer Res. 2010 Jun 15;70(12):5184-93
references.pmid: 20501828
references.citation: Expert Rev Anticancer Ther. 2011 Aug;11(8):1181-92
references.pmid: 21916571
references.citation: Exp Ther Med. 2013 Jan;5(1):338-342
references.pmid: 23251295
references.citation: Invest Ophthalmol Vis Sci. 2009 Sep;50(9):4429-35
references.pmid: 19369237
references.citation: Hepatology. 2012 Jun;55(6):1852-62
references.pmid: 22234835
references.citation: J Biol Chem. 1993 Feb 15;268(5):3734-8
references.pmid: 8429048
references.citation: Cancer Res. 2012 Apr 1;72(7):1836-43
references.pmid: 22311674
references.citation: Cancer Res. 2008 Sep 15;68(18):7409-18
references.pmid: 18794129
references.citation: Diabetes. 2013 Mar;62(3):887-95
references.pmid: 23223022
references.citation: Mol Cell. 2006 Apr 21;22(2):159-68
references.pmid: 16603397
references.citation: J Cell Biol. 2010 Jun 28;189(7):1157-69
references.pmid: 20566686
references.citation: N Engl J Med. 2007 May 31;356(22):2271-81
references.pmid: 17538086
references.citation: J Cell Biol. 2011 Jan 10;192(1):69-81
references.pmid: 21200031
references.citation: Science. 1995 Oct 6;270(5233):50-1
references.pmid: 7569949
references.citation: Cancer Res. 2010 Oct 15;70(20):8097-107
references.pmid: 20876803
references.citation: Kidney Int. 1996 Jan;49(1):209-16
references.pmid: 8770969
references.citation: Carcinogenesis. 2012 Dec;33(12):2391-7
references.pmid: 22983984
references.citation: Blood. 2012 Jan 12;119(2):476-87
references.pmid: 22080480
references.citation: N Engl J Med. 2012 Feb 9;366(6):520-9
references.pmid: 22149876
references.citation: Science. 2005 Feb 18;307(5712):1098-101
references.pmid: 15718470
references.citation: Mol Cancer Ther. 2011 Aug;10(8):1394-406
references.pmid: 21673091
references.citation: J Biol Chem. 2013 Mar 1;288(9):6034-44
references.pmid: 23300087
references.citation: BMC Cancer. 2012 Nov 23;12:546
references.pmid: 23173671
references.citation: Drug Discov Today. 2007 Feb;12(3-4):112-24
references.pmid: 17275731
references.citation: Eur Heart J. 2013 Nov;34(44):3400-2
references.pmid: 23391580
references.citation: Front Mol Neurosci. 2011 Dec 02;4:51
references.pmid: 22144946
references.citation: J Biol Chem. 2009 Mar 20;284(12):8023-32
references.pmid: 19150980
references.citation: N Engl J Med. 2010 Nov 4;363(19):1801-11
references.pmid: 21047224
references.citation: Circulation. 2004 Jun 1;109(21):2587-93
references.pmid: 15136501
references.citation: Sci Signal. 2009 Apr 21;2(67):pe24
references.pmid: 19383975
references.citation: Nature. 1994 Jun 30;369(6483):756-8
references.pmid: 8008069